The verdict
Our read at a glance.
Whether potential addiction-treatment signals can be studied in a standardized way that addresses cardiac and neurologic safety risks.
- The signal
- There are observational and translational signals, but safety literature includes serious cardiac-risk concerns.
- The unknown
- Whether a regulated clinical pathway can separate any therapeutic signal from unacceptable acute risk.
- Our read
- The safety boundary is not a footnote; it is the center of the evidence map.
The mechanism
How it works.
Ibogaine is a plant alkaloid from the iboga shrub, and the body converts much of it into a long-lasting metabolite, noribogaine. Both act on many targets at once, including opioid receptors, the NMDA glutamate receptor, the serotonin transporter, nicotinic receptors, and sigma receptors, with no single one explaining its effects. The proposed reason it blunts opioid withdrawal and craving is that this simultaneous hit across reward and withdrawal circuits transiently resets them, but this rests on observational reports and animal work rather than controlled human trials, and the same broad activity drives its serious cardiac risk.
Safety & regulatory boundary
The consequential part.
This is a safety/regulatory watch item. The Watchlist does not provide clinic, sourcing, or use guidance.
What's next
What we're watching.
Controlled trials, cardiac monitoring standards, analog development, and regulatory decisions.
Context
Why this is discussed.
Ibogaine is discussed for opioid and substance-use disorders, often by people seeking options after failed standard approaches.
The evidence base
2 cited references.
Indexed literature (PubMed)2
Scoping review authors · 2026
Clinical toxicology authors · 2019
Keep reading